whats new in amd - 2012
DESCRIPTION
Update on the latest research into age-related macular degenerationTRANSCRIPT
![Page 1: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/1.jpg)
What’s New in AMD
Rick Trevino, OD, FAAOSchool of Optometry
University of the Incarnate Word
![Page 2: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/2.jpg)
What’s New in AMD
10. Drug Pipeline
![Page 3: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/3.jpg)
“It is difficult to make predictions, especially about the future.”
![Page 4: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/4.jpg)
Drug Pipeline
• Geographic Atrophy– Fenretinide (ReVision)
• Visual cycle modulator, Phase 3 clinical trial
– ACU-4429 (Acucela)• Visual cycle modulator, Phase 2 clinical trial (ENVISION Clarity
Trial)
– POT-4 (Potentia/Alcon)• Complement-3 inhibitor (anti-inflammatory), Phase 2 clinical
trials
– NT-501 (Neurotech)• Ciliary neurotrophic factor (neuroprotection), Phase 3 clinical
trials
![Page 5: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/5.jpg)
Drug Pipeline
• NT-501 (Neurotech)– Ciliary neurotrophic factor (CNF) is a potent
neuroprotective agent that affects the survival of cells in the nervous system, including retinal cells
– Human cells genetically modified to secrete CNF are placed within a semipermiable capsule which is then implanted within the vitreous
– The sustained release capsule will deliver CNF to the retina for a year or longer
neurotechusa.com
![Page 6: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/6.jpg)
Ciliary neurotrophic factor is delivered to the retina via encapsulated cell technology (ECT). ECT implants consist of human cells that have been genetically modified to produce a specific therapeutic protein and encapsulated in a semi-permeable hollow fiber membrane. The cells continuously produce the therapeutic protein which diffuses out of the implant at the target site.
![Page 7: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/7.jpg)
Drug Pipeline
• Zhang (2011)– Multicenter, 1yr, double-masked, sham-controlled
dose-ranging, phase 2 study– CNTF treatment resulted in a dose-dependent
increase in retinal thickness– Average change in VA
• 0.8 mean letter gain in the high-dose group • 9.7 mean letter loss in the combined low-dose/sham group
– VA stabilization rates (loss of <15 letters)• 96.3% high-dose, 83.3% low-dose, 75% sham group
Zhang K, Proc Natl Acad Sci U S A. 2011;108:6241-5
![Page 8: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/8.jpg)
Effect of intraocular CNTF on visual acuity stabilization.
(A) Percentage of subjects losing <15 letters from baseline over 12 mo.
(B) Significant effect of CNTF on visual acuity stabilization in the high-dose group with baseline BCVA at 20/63 or better.
![Page 9: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/9.jpg)
Drug Pipeline
• Conclusion– “These findings suggest that CNTF delivered by the
encapsulated cell technology implant appears to slow the progression of vision loss in GA, especially in eyes with 20/63 or better vision at baseline”
Zhang K, Proc Natl Acad Sci U S A. 2011;108:6241-5
![Page 10: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/10.jpg)
What’s New in AMD
9. Implantable Miniature Telescope10. Drug Pipeline
![Page 11: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/11.jpg)
Implantable Miniature Telescope
• The FDA approved the Implantable Miniature Telescope (IMT) in 2010 to improve vision in patients 75yrs and older with stable severe-to-profound vision impairment (20/160 to 20/800) caused by bilateral end-stage AMD
• IMT produced by VisionCare Ophthalmic Technologies and marketed as CentraSight
![Page 12: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/12.jpg)
The housing measures 3.6 mm in diameter and 4.4 mm in length in a PMMA carrier with haptics measuring 13.5 mm in diameter designed to be implanted “in the bag”
![Page 13: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/13.jpg)
Implantable Miniature Telescope
• IMT is implanted into one eye only, as determined by patient and doctor (typically the non-dominant or poorer seeing eye)
• Functions as a fixed focus 2.2x or 2.7xtelescope system(2 models available)
• Generates a 20° to24° field of view (depending on mag)
![Page 14: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/14.jpg)
Implantable Miniature Telescope
• The size of the device requires a 12 mm limbal incision and is closed with 10.0 nylon sutures
• Most common adverse event is persistent vision-impairing corneal edema (9.2% 5-year cumulative probability)
![Page 15: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/15.jpg)
Implantable Miniature Telescope
Implantable Miniature Telescope Professional Use Information, FDA-approved product labeling.
![Page 16: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/16.jpg)
Implantable Miniature Telescope
• Partial contraindications list:– Active CNV or tx for CNV within the past 6 mos– Previous intraocular or cornea surgery– Peripheral vision loss in the fellow eye– Central anterior chamber depth (ACD) <3.0 mm– Myopia > 6.0 D or hyperopia > 4.0 D in the operative eye– Presence of corneal guttata– Failure meet the minimum age (75 yrs) and endothelial
cell density requirements• Age 75-84: 2000 cells/mm2
• Age ≥85: 1800 cells/mm2
Implantable Miniature Telescope Professional Use Information, FDA-approved product labeling.
![Page 17: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/17.jpg)
Implantable Miniature Telescope
• Requirements prior to surgery:– Evidence of visually significant cataract (>Grade 2)– Confirm geographic atrophy or disciform scar with
foveal involvement in both eyes– Undergo training and assessment with low vision
specialist in the use of an external telescope for the patient to make an informed decision
– Agree to participate in post-operative visual training with a low vision specialist.
Implantable Miniature Telescope Professional Use Information, FDA-approved product labeling.
![Page 18: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/18.jpg)
Implantable Miniature Telescope
• IMT Treatment ProgramSTEP 1: Patient Diagnosis and Management : Retina Specialist
STEP 2: Evaluation (Low Vision Assessment/Eye Selection): Low Vision Optometrist
STEP 3: Implantation: Cornea/Cataract Surgeon
STEP 4: Visual Training/Rehabilitation: Low Vision Optometrist and Occupational Therapist
– All providers must receive training before becoming a CentraSight program provider
centrasight.com
![Page 19: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/19.jpg)
Implantable Miniature Telescope
• Patient selection– Management of goals and expectations– Visual function questionnaires, cognitive
evaluation, and depression screens– Mobility evaluations
• Eye selection– Worse eye: Less risk if procedure fails– Better eye: Improved functioning if procedure
successful
Primo SA. Optometry. 2010;81:86-93
![Page 20: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/20.jpg)
Implantable Miniature Telescope
• Summary– Supplements conventional low vision aids for
persons with end-stage bilateral AMD – Significant surgical complications and post-
operative adverse events can lead to profound vision loss
– Strict pre-operative evaluation protocols designed to select those candidates most likely to succeed with IMT
![Page 21: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/21.jpg)
What’s New in AMD
8. Aspirin9. Implantable Miniature Telescope10. Drug Pipeline
![Page 22: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/22.jpg)
Aspirin & AMD
• Four major pharmacologic properties of acetylsalicylic acid (ASA)– Analgesic: Inhibits pain via multiple mechanisms– Antipyretic: Lowers body temperature of persons with
fever– Anti-inflammatory: Inhibition of
prostaglandins, generation of lipoxins
– Antiplatelet: Decreases the aggregability of platelets and the formation of intra-arterial thrombi
Schror K. Aspirin Update. International Press Workshop 2008
![Page 23: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/23.jpg)
Aspirin & AMD
• Aspirin for the primary prevention of disease– Prevent of cardiovascular events, reduce the risk of some
cancers, reduced risk of Alzheimer's disease– Approximately 36% of adults take aspirin regularly for primary
prevention of disease• Adverse effects of aspirin
– Gastrointestinal hemorrhage, worsen hypertension, renal failure, aggravate asthma, hemorrhagic stroke
– Each year 16,500 deaths are related to aspirin and NSAID useSeshasai SR, et al. Arch Intern Med. 2012;172:209-16
![Page 24: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/24.jpg)
Aspirin & AMD
Harmful Effect• Feman (1972)• Bloome (1978)• Kingham (1988)• Lewis (1988)• AREDS (2000)• de Jong (2012)
Protective Effect• Christen (2001)• Christen (2009)
No Effect• MPS Group (1986)• MPS Group (1990)• Klein (1991)• Hirvela (1996)• Klein (2001)• Douglas (2007)• Rudnicka (2010)
![Page 25: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/25.jpg)
Aspirin & AMD
• Antiplatelet effect– Enhance circulation and decrease the risk of
vascular events could decrease the risk of AMD– Risk of macular hemorrhage associated with use
of anticoagulants and aspirin • Anti-inflammatory effect
– Aspirin could decrease the risk of AMD through though its anti-inflammatory effects
Christen WG. Ophthalmology. 2009; 116: 2386–2392.
![Page 26: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/26.jpg)
Aspirin & AMD
• Christen (2009)– Effect of ASA use on AMD development
prospectively studied in a randomized, double-masked, placebo-controlled trial of 39,876 healthy adult women over an average of 10 years
– Low-dose aspirin had a non-significant 18% reduced risk of visually-significant AMD compared to women assigned to placebo (hazard ratio, 0.82; 95% CI, 0.64 to 1.06).
Christen WG. Ophthalmology. 2009; 116: 2386–2392.
![Page 27: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/27.jpg)
Christen WG. Ophthalmology. 2009; 116: 2386–2392.
![Page 28: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/28.jpg)
Aspirin & AMD
• de Jong (2012)– Study AMD development in 4691 participants
aged 65 years and older in the population-based cross-sectional European Eye Study in 7 European communities
– Frequent aspirin use was associated with early and wet late AMD, and the odds ratios rose with increasing frequency of consumption
de Jong, et al. Ophthalmology. 2012;119:112–118
![Page 29: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/29.jpg)
de Jong, et al. Ophthalmology. 2012;119:112–118
![Page 30: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/30.jpg)
Aspirin & AMD
• Summary– Biologically plausible basis for protective effect
(improved circulation, anti-inflammatory)– ASA use does not increase the risk of macular
bleeding, but if bleeding occurs it may be more severe if anticoagulants or ASA are being used.
– Studies to date do not clearly demonstrate either a beneficial or harmful effect of low-dose ASA use on the development or progression of AMD
![Page 31: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/31.jpg)
What’s New in AMD
7. Lifestyle8. Aspirin9. Implantable Miniature Telescope10. Drug Pipeline
![Page 32: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/32.jpg)
Lifestyle & Behavioral Factors
• Modifiable risk factors related to lifestyle that have been associated with AMD– Smoking– Physical activity– Diet
• AMD has been associated with chronic diseases or conditions which can be modified by lifestyle choices– Cardiovascular disease– Diabetes & Hypertension– Obesity– Elevated markers of inflammation
Mares JA, et al. Arch Ophthalmol. 2011;129:470–480
![Page 33: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/33.jpg)
Lifestyle & Behavioral Factors
• Smoking– Smoking is the most significant modifiable risk factor
for AMD– Estimated that 29% of all AMD cases can be
attributed to smoking – Dose-response: Increased risk with more pack-years– Reversibility: Risk declines following smoking
cessation, but does not return to baseline– Exposure to environmental (second-hand) smoke has
not been associated with AMD
![Page 34: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/34.jpg)
Chakravarthy (2010): Meta-analysis of studies assessing risk of advanced AMD (combined atrophic and exudative) associated with smoking.
CC: case control, CS: cross-sectional, PC: prospective cohort
![Page 35: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/35.jpg)
Warning label on cigarettes sold in Australia
![Page 36: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/36.jpg)
Lifestyle & Behavioral Factors
• Obesity– Most but not all studies have found a positive
association between obesity and AMD– Obesity may have a role in the development of
AMD because of its associated hyperleptinemia-induced oxidative stress
– Decreasing abdominal obesity results in a lower risk for AMD. Suggests a role of weight loss in preventing the development of AMD
Peeters A, et al. Arch Ophthalmol. 2008;126(11):1554-1560
![Page 37: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/37.jpg)
Chakravarthy (2010): Meta-analysis of studies assessing risk of advanced AMD (combined atrophic and exudative) associated with BMI.
![Page 38: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/38.jpg)
Risk of offending patients when obesity is discussed
![Page 39: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/39.jpg)
Lifestyle & Behavioral Factors
• Exercise– Physical activity lowers cardiovascular disease risk,
which is possibly predictive of AMD. • Activity improves various risk factors associated with AMD
risk : adiposity and blood pressure.
– Seddon (2003): vigorous activity associated with a 25% reduction in progression to advanced AMD
– BDES (2006): Regular physical activity reduced the cumulative incidence of exudative AMD
![Page 40: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/40.jpg)
Williams (2009)Dose-response relationshipRelative risk of AMD by average distance run per day in 41,708 nondiabetic, nonsmoking men and women
![Page 41: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/41.jpg)
Lifestyle & Behavioral Factors
What’s Good for the Heart
Is also Good for the Eye!
Don’t smokeLose weight
Exercise regularly
![Page 42: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/42.jpg)
What’s New in AMD
6. Sunlight and Cataract Surgery7. Lifestyle8. Aspirin9. Implantable Miniature Telescope10. Drug Pipeline
![Page 43: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/43.jpg)
• Photochemical damage occurs when low wavelength light is absorbed by photoreactive pigments in the retina, such as lipofuscin, causing release of reactive oxygen species
• Speculate that chronic exposure to low wavelength light may overwhelm normal defense and repair mechanisms
• Inconsistent association with AMD risk
Sunlight & Cataract Surgery
Chalam KV, et al. Eye & Contact Lens. 2011;37:225–232
![Page 44: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/44.jpg)
Sunlight & Cataract Surgery
• Sunlight exposure– Chesapeake Bay Waterman Study (1992): Subjects
exposed to long-term high doses of blue light were found to have a higher incidence of advanced AMD
– BMES (1998): Persons with sun-sensitive skin (burning rather than tanning) demonstrated increased risk of neovascular AMD
– Hirakawa (2008): Greater total lifetime exposure to sunlight as objectively measured using facial wrinkling associated with greater risk of late AMD
![Page 45: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/45.jpg)
Hirakawa M. Br J Ophthalmol. 2008;92:630-634
![Page 46: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/46.jpg)
Sunlight & Cataract Surgery
• BDES (2004)– Ten-year follow-up of 2764 participants in the
Beaver Dam Eye Study– Persons exposed to the summer sun for >5 hrs per
day in youth or at baseline were at higher risk of early AMD than those exposed <2 hrs per day
– A protective effect of hat and sunglass use was found for those participants with highest amount of sun exposureTomany SC., et al. Arch Ophthalmol. 2004;122:750-7
![Page 47: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/47.jpg)
Sunlight & Cataract Surgery
• Fletcher (2008)– Population-based study of 4700 people in 7
European countries– High sunlight exposure and low serum antioxidant
levels associated with 4-fold increased risk of wet AMD
– Sunlight not hazardous if antioxidant levels are adequate
– Risk greatest with low levels of zeaxanthin, vitamin E, and vitamin C
Fletcher AE., et al. Arch Ophthalmol. 2008;126:1396-1403
![Page 48: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/48.jpg)
Sunlight & Cataract Surgery
• Cataract Surgery– The adult lens absorbs nearly 100% of light below
400nm– Following cataract surgery increased
exposure to short-wavelength light may increase the risk of photochemical damage to the retina
– Inconsistent association with AMD risk
Bockelbrink A., et al. Surv Ophthalmol 2008;53:359-367
![Page 49: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/49.jpg)
Sunlight & Cataract Surgery
• AREDS (2009): – Found no clinically important increased risk of progression
to advanced AMD after cataract surgery – AREDS is the only prospective study in which the severity
of AMD was documented before and after cataract surgery in a large number of cases with more than 5 years of regular follow-up
– Absence of any consistent pattern in the direction of harm across models reinforces the conclusion that AREDS data provide little evidence that cataract surgery increases the risk of progression to late AMD.
Chew EY, et al. Ophthalmology 2009;116:297–303
![Page 50: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/50.jpg)
Chakravarthy (2010): Meta-analysis of studies assessing risk of advanced AMD (atrophic and exudative) associated with cataract surgery.
![Page 51: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/51.jpg)
Sunlight & Cataract Surgery
• Blue-blocking IOL Controversy– Most modern IOLs filter UV radiation below
400nm. – The crystalline lens turns yellow with age, thereby
blocking some blue light, while most IOLs are transparent
– Blue-blocking IOLs are designed to simulate transmission characteristics of the adult non-cataractous human lens offering theoretical AMD protection
Wong IYH, et al. Int Ophthalmol. 2011;31:73–82
![Page 52: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/52.jpg)
Turner (2008): Spectral sensitivity of photopic, scotopic and circadian (melatonin suppression) photoreception
![Page 53: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/53.jpg)
Sunlight & Cataract Surgery
• Blue-blocking IOL Controversy– Concerns have been raised that blue-blocking IOLs
attenuate visual performance under scotopic conditions, have undesirable effects on color perception, and disrupt circadian entrainment
– There is currently no evidence of any clinically harmful effects of blue-blocking IOLs
– There is currently no evidence of any clinically beneficial effects of blue-blocking IOLs
Henderson BA. Surv Ophthalmol 2010;55:284-289
![Page 54: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/54.jpg)
Sunlight & Cataract Surgery
• Summary– There is some evidence that removal of a
cataractous lens may increase the risk of AMD progression due to an increase in retinal short wavelength light exposure
– This risk could possibly be mitigated if IOLs filtered UV and short wavelength visible light
– The theoretical disadvantages of blue-light filtering IOLs may be minimized by filtering only violet light
![Page 55: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/55.jpg)
What’s New in AMD
5. Lutein6. Sunlight and Cataract Surgery7. Lifestyle8. Aspirin9. Implantable Miniature Telescope10. Drug Pipeline
![Page 56: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/56.jpg)
Lutein
• Macular Pigment– As the major components of macular pigment,
lutein and zeaxanthin are concentrated at the macula suggesting a possible role in preventing the onset and progression of macular disease.
– Laboratory data suggest an important role for these two carotenoids in protecting the neural retina from photo-oxidative damage by absorbing blue light and by quenching reactive oxygen species through powerful antioxidant activity.
![Page 57: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/57.jpg)
![Page 58: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/58.jpg)
Lutein
• Weigert (2011)– Dietary lutein supplementation can significantly increase
macular pigment optical density (MPOD). – Patients with the lowest MPOD at baseline experience
the greatest increase– Patients with high MPOD at baseline experience almost
no increase, suggesting that lutein incorporation in the retina is saturable
– Increasing MPOD may be associated with improvements in visual function (including improved VA) due to decreased chromatic aberration
Weigert A, et al. Invest Ophthalmol Vis Sci. 2011;52:8174–8178
![Page 59: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/59.jpg)
Weigert (2011): Correlation between MPOD at baseline and the change in MPOD after 6 months of lutein supplementation.
Normal Range
![Page 60: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/60.jpg)
Weigert (2011): Correlation between the change in MPOD and the change in VA after 6 months of lutein supplementation.
![Page 61: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/61.jpg)
Lutein
• Ma (2012)– Meta-analysis of 6 longitudinal cohort studies
evaluating the relationship between dietary intake of lutein and zeaxanthin and AMD risk
– Relative risk for early AMD: 0.96 (0.78-1.17) comparing the highest with the lowest category of lutein and zeaxanthin intake
– Relative risk for late AMD: 0.74 (0.57-0.97)– Dietary intake of lutein and zeaxanthin may
decrease the risk of late but not early AMDMa L, et al. Br J Nutr. 2012;107:350-9.
![Page 62: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/62.jpg)
![Page 63: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/63.jpg)
Lutein
• Summary– Lutein supplementation will improve MPOD in
patients with low levels of macular pigment, and these patients will benefit visually from this intervention
– It remains unclear to what extent lutein supplementation or MPOD influences the onset and progression of AMD
• This question is being investigated in AREDS 2
![Page 64: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/64.jpg)
What’s New in AMD
4. Fish5. Lutein6. Sunlight and Cataract Surgery7. Lifestyle8. Aspirin9. Implantable Miniature Telescope10. Drug Pipeline
![Page 65: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/65.jpg)
Fish
• Fish oil is rich in omega-3 long-chain polyunsaturated fatty acids (LCPUFA). – Docosahexaenoic acid (DHA) is the major dietary
and structural omega-3 LCPUFA of the retina– Eicosapentaenoic acid (EPA) is a precursor to DHA
• LCPUFAs may protect against oxygenic, inflammatory, and age-associated pathology
![Page 66: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/66.jpg)
Fish
• Chong (2008)– Meta-analysis of 9 studies finds that consumption of
fish twice or more per week and foods rich in omega-3 fatty acids was associated with a reduced risk of both early and late AMD.
• AREDS (2009)– Participants reporting the highest consumption of fish
oil were approximately 30% less likely to develop advanced AMD than participants reporting the lowest fish oil consumption
![Page 67: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/67.jpg)
Fish
• Christen (2011)– Prospective study of 38,000 females over 10 years– Women who consumed 1 or more servings of fish
per week, compared with those who consumed less than 1 serving per month, had a relative risk of AMD of 0.58
– Strongest observational evidence to date in support of a possible role for intake of omega-3 long-chain fatty acids and fish in the primary prevention of AMD
Christen WG, et al. Arch Ophthalmol. 2011;129(7):921-929
![Page 68: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/68.jpg)
Intake of Fish Relative Risk (95% CI) P
Total fish 0.58 (0.38 – 0.87) 0.001
Dark-meat fish (salmon, tuna) 0.56 (0.32 – 0.99) 0.01
Canned tuna fish 0.56 (0.40 – 0.80) 0.001
Shrimp / lobster / scallops 1.28 (0.77 – 2.13) 0.69
Other fish 0.72 (0.51 – 1.01) 0.06
Fish
Christen WG, et al. Arch Ophthalmol. 2011;129(7):921-929
Diagnosis of Visually Significant Age-Related Macular Degeneration According to Categories of Fish Intake in the Women’s Health Study
Comparing risk associated with less than once per month consumption to once per week or greater consumption. Visually significant AMD is defined as AMD severe enough to cause a decline in visual acuity to 20/30 or worse
![Page 69: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/69.jpg)
Fish
• Summary– Strong and consistent observational evidence that
fish and omega-3 fatty acid consumption is protective against early and late AMD
– Value of fish oil supplementation in slowing progression to advanced AMD is being tested in AREDS 2
![Page 70: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/70.jpg)
What’s New in AMD
3. Anti-VEGF medications4. Fish5. Lutein6. Sunlight and Cataract Surgery7. Lifestyle8. Aspirin9. Implantable Miniature Telescope10. Drug Pipeline
![Page 71: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/71.jpg)
Anti-VEGF Medications
• Bind to VEGF preventing it from binding to its target receptor on endothelial cells– Decrease growth of and leakage from CNV– Prevents moderate and severe vision loss– Frequently leads to vision improvement
• Three anti-VEGF drugs FDA-approved for AMD, plus one used extensively off-label– Pegaptanib sodium (Macugen)– Ranibizumab (Lucentis)– Aflibercept (Eylea, VEGF-Trap)– Bevacizumab (Avastin)
![Page 72: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/72.jpg)
Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR2) on the surface of vascular endothelial cells and triggers a number of metabolic pathways that promotes and supports the growth of new blood vessels, a process known as angiogenesis
![Page 73: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/73.jpg)
Avastin: Humanized mouse anti-VEGF monoclonal antibodyLucentis: Antigen-binding fragment modified to increase affinity for anti-VEGF
![Page 74: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/74.jpg)
Anti-VEGF Medications
• Which is better, Lucentis or Avastin?– Both drugs have the same mechanism of action, but
very different structures– Lucentis is much more expensive than Avastin
• Lucentis costs $2000 per dose compared to $50 for Avastin
• Introduction to Eylea– The newest drug to be FDA approved for AMD,
became commercially available in November 2011– Primary advantage is that it’s recommended dosage is
q2mos, compared to q1mo for Lucentis
![Page 75: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/75.jpg)
Avastin is the most popular drug used in the treatment of neovascular AMD, but the vast majority of the cost is for the much more expensive Lucentis
![Page 76: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/76.jpg)
CATT Study
• NIH-sponsored head-to-head comparison of Lucentis and Avastin
• The safety and efficacy of Lucentis for wet AMD has been established by clinical trials
• Because of it’s significant cost advantage, Avastin has become the most popular drug in the USA for the treatment of wet AMD despite the absence of any large-scale clinical trials supporting it’s use.
Martin DF, et al. N Engl J Med. 2011;364:1897–1908
![Page 77: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/77.jpg)
CATT Study
• Methods– Multicenter, single-blind, non-inferiority trial– 1208 patients with neovascular AMD were
randomly assigned to receive intravitreal Lucentis or Avastin on either a monthly schedule or as needed (PRN) with monthly evaluation x 1yr
– 4 study groups:• Lucentis monthly, Lucentis PRN• Avastin monthly, Avastin PRN
Martin DF, et al. N Engl J Med. 2011;364:1897–1908
![Page 78: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/78.jpg)
CATT Study
• Results: Visual Acuity– Avastin administered monthly was equivalent to
Lucentis administered monthly, with 8.0 and 8.5 letters gained, respectively.
– PRN Avastin was equivalent to PRN Lucentis, with 5.9 and 6.8 letters gained, respectively
– PRN Lucentis was equivalent to monthly Lucentis • 1.7 fewer letters on PRN dosing
– The comparison between PRN Avastin and monthly Avastin was inconclusive
• 2.6 fewer letters on PRN dosing
Martin DF, et al. N Engl J Med. 2011;364:1897–1908
![Page 79: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/79.jpg)
Martin DF, et al. N Engl J Med. 2011;364:1897–1908
![Page 80: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/80.jpg)
CATT Study
• Results: Anatomy– The mean decrease in central retinal thickness
was greater in the Lucentis-monthly group (196 µm) than in the other groups (P = 0.03)
– All other anatomic results also indicate superior efficacy of Lucentis
• Resolution of fluid on OCT (P < 0.001) • Cessation of leak on fluorescien
angiography (P < 0.001)
![Page 81: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/81.jpg)
A stronger effect on leakage by Lucentis might eventually lead to actual differences in visual acuity outcomes over time
![Page 82: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/82.jpg)
CATT Study
• Results: Safety– The proportion of patients with serious systemic
adverse events (primarily hospitalizations) was higher with Avastin than with Lucentis
• Avastin: 24.1% vs. Lucentis 19.0%• Risk ratio, 1.29; 95% CI, 1.01 - 1.66
– Life-threatening or disabling events occurred in 3.51% of the combined Lucentis and 5.61% of the combined Avastin groups (P = 0.04)
– 1.5% of patients treated with Lucentis and 2.5% of patients taking Avastin diedMartin DF, et al. N Engl J Med. 2011;364:1897–1908
![Page 83: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/83.jpg)
![Page 84: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/84.jpg)
CATT Study
• Two plausible interpretations of CATT results– Avastin is almost as good as Lucentis, and costs less
• The differences in efficacy are not statistically or clinically significant
• The differences in safety signals may be attributable to chance, or imbalances in baseline health status
– Avastin is not as good as Lucentis with more adverse reactions
• In light of significant anatomic differences it is hard to justify calling the efficacy equivalent
• Safety data contain some worrisome and important signals which should not be minimized or ignored
![Page 85: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/85.jpg)
Avastin Safety
• Ocular safety concerns– Episodic severe uveitis (sterile endophthalmitis)
• Clusters of cases have been documented associated with specific batches of Avastin in the USA, Canada and Japan
• Trace endotoxin contamination suspected
– Sustained IOP elevation reported much more frequently after Avastin injection than Lucentis
• Etiology unknown. • Possibilities include low-grade inflammatory reactions,
direct drug toxicity or mechanical obstruction of the trabecular meshwork
![Page 86: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/86.jpg)
![Page 87: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/87.jpg)
Avastin Safety
• Systemic safety concerns– Retrospective analysis of 146,942 Medicare records
• 11% higher risk in all-cause mortality and 57% higher risk of hemorrhagic stroke with Avastin vs Lucentis
– BEAT-ROP study• Higher mortality rate with Avastin than laser (6.6% vs
2.6%)
– Cancer deaths• Compared with chemotherapy alone, the addition of
Avastin was associated with an increased risk of fatal adverse events, with a relative risk of 1.46
Lim LS, et al. Am J Ophthalmol. 2011;152:329-31.
![Page 88: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/88.jpg)
Avastin Safety
• Summary– Significant safety concerns exist regarding off-label
intravitreal Avastin use • Ocular toxicity, compounding
practice, systemic effects
– Awaiting 2-year results of CATT for clearer evidence of relative safety and efficacy of Avastin and Lucentis
– In the meanwhile, intravitreal Avastin should be used with caution
![Page 89: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/89.jpg)
Eylea
• The importance of dosing– Lucentis pivotal clinical trials utilized a monthly
monitoring and dosing paradigm• Monthly injections create a significant hardship for
patients• Intravitreal injections are not risk free
– Attempts to reduce the frequency of injection by employing extended dosing paradigms guided by eye examinations and monitoring
• Clinical studies uniformly demonstrate decline in visual acuity gains with less than monthly dosing
![Page 90: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/90.jpg)
Monthly dosing: MARINA studyRosenfield PJ, et al. N Engl J Med. 2006;355:1419-1431
![Page 91: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/91.jpg)
Quarterly dosing: PIER studyRegillo CD, et al. Am J Ophthalmol 2008;145:239–248
![Page 92: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/92.jpg)
As-needed dosing: SAILOR studyBoyer DS, et al. Ophthalmology 2009;116:1731–1739
![Page 93: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/93.jpg)
The HORIZON study was a 24-month extension of the FOCUS, MARINA and ANCHOR trials. Treated patients were switched from fixed monthly dosing to as needed upon entering HORIZON. Three groups of patients were always treated, never treated, and cross-over patients who were initially untreated and later treated.
![Page 94: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/94.jpg)
• Need for a neovascular AMD treatment option that can maintain visual acuity gains with less frequent intravitreal injections– Frequent office visits pose a
challenge for patients in terms of travel and visit time
– Retinal practices are burdened with frequent visits
• Need a wet AMD therapy that can deliver consistent efficacy with a more convenient, predictable, less frequent monitoring and dosing regimen
Eylea
Heier J. Regeneron Investor Briefing. 2/13/2011
![Page 95: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/95.jpg)
Eylea
• Aflibercept (Eylea, VEGF-Trap)– Receptor decoy– Recombinant chimeric
molecule – Contains the VEGF-binding
elements from VEGF receptors 1 and 2 fused to human antibody.
– Eylea binds all VEGF-A isoforms and placental growth factor
Zampros I, et al. J Ophthalmol. 2012;2012:319728
![Page 96: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/96.jpg)
Top. A key binding domain of VEGFR1 and a key binding domain of VEGFR2 (left) are fused for tight binding affinity for both VEGF-A isomers and PlGF (center). Two dual-domain arms are used for one aflibercept molecule to mimic the natural receptor (right).
Bottom. The Fc portion of IgG1 (left) is fused to the two dual-domain arms (center) resulting in the engineered molecule of aflibercept (right).
![Page 97: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/97.jpg)
Eylea
• Phase 3 clinical trials– Two identical studies in different geographic
regions• VIEW 1: USA and Canada• VIEW 2: Europe, Latin America, and Japan
– Test two doses at monthly injection frequency and higher dose at bimonthly frequency for 1 year
– PRN dosing, with a dose administered at least every 3 mos (but not more often than monthly), is being evaluated during year 2 of the study
Heier J. Regeneron Investor Briefing. 2/13/2011
![Page 98: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/98.jpg)
Heier J. Regeneron Investor Briefing. 2/13/2011
![Page 99: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/99.jpg)
Heier J. Regeneron Investor Briefing. 2/13/2011
![Page 100: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/100.jpg)
Heier J. Regeneron Investor Briefing. 2/13/2011
![Page 101: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/101.jpg)
Heier J. Regeneron Investor Briefing. 2/13/2011
![Page 102: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/102.jpg)
Heier J. Regeneron Investor Briefing. 2/13/2011
![Page 103: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/103.jpg)
• Safety– No significant difference in rates of ocular or systemic adverse
events when compared to Lucentis• Conclusions
– All Eylea dosing groups were demonstrated non-inferior to monthly Lucentis
– Eylea dosed every two months was similar in efficacy and safety to Lucentis dosed monthly
– Potential for a new, more predictable and less burdensome treatment paradigm
Eylea
Heier J. Regeneron Investor Briefing. 2/13/2011
![Page 104: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/104.jpg)
What’s New in AMD
2. Genetics3. Anti-VEGF medications4. Fish5. Lutein6. Sunlight and Cataract Surgery7. Lifestyle8. Aspirin9. Implantable Miniature Telescope10. Drug Pipeline
![Page 105: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/105.jpg)
Genetics
• Besides age, genetic background is the most significant non-modifiable risk factor for AMD– Smoking is the most significant modifiable risk factor
• The degree of heritability and the relative role of genetic and environmental factors is still unknown
• Seddon (2005): US Twin Study of AMD– Genetic factors explain 46% - 71% of disease severity– Environmental factors explain 19% - 37%
![Page 106: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/106.jpg)
Genetics
• Genes associated with AMD– Alternative complement pathway
• CFH, C2, CFB, C3, CFI
– ARMS2/HTRA1 region • Function unknown
– High density lipoprotein (HDL) cholesterol pathway • LIPC, ABCA1, CETP
– Extracellular matrix pathway • TIMP3, COL10A1, COL8A1
– Angiogenesis pathway • VEGFA
– Vitamin D pathway• CYP24A1
Yu Y, et al. Invest Ophthalmol Vis Sci. 2012 Jan 12. [Epub ahead of print]
CFH and ARMS2/HTRA1 account for approximately 40% to 60% of the genetic risks of AMD in whites
![Page 107: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/107.jpg)
Risk of AMD based upon ARMS2 and CFH genotype
TTTC
CC
GG
GT
TT
0
10
20
30
40
50
60
CFH
ARMS2
AM
D O
DD
S R
AT
IO (
%)
Rivera A, et al. Hum Mol Genet. 2005;14:3227-36
![Page 108: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/108.jpg)
Genetics
• Risk modeling– Mathematical models that attempt to predict the risk of
developing advanced AMD based upon genetic, phenotypic and behavioral factors
• Pharmacogenomics– Attempts to define the
genetic variants that determine variable response to medication.
– The ultimate goal is to identify those who respond best and avoid adverse reactions
![Page 109: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/109.jpg)
Risk Models
• Use of mathematical models to predict risk of developing advanced AMD based upon genotype and environmental risk factors
• A genetic test identifying individuals at high risk of developing CNV holds the promise for earlier detection through risk-based surveillance protocols and improved outcomes from more timely intervention
![Page 110: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/110.jpg)
Genetic testing services are currently available, including tests for AMD
![Page 111: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/111.jpg)
Risk Models
• Two types of models– Genetic only
• Risk factors are static through life and not subject to misreporting
– Genetic plus other factors • May include phenotype, behavioral and environmental
factors in the model• Potential for improvement of short-term risk assessment• Unclear how to account for change over time (smoking
behavior, weight loss)
![Page 112: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/112.jpg)
Risk Models
• Jakobsdottir (2009)– Genetic only model using 3 SNPs– AUC: 0.79 (a measure of how well a test can
distinguish between cases and controls)• Seddon (2009)
– Joint gene–environment model using six-SNPs– AUC: 0.81– Can distinguish between “progressors” and “non-
progressors” and between non-disease controls from patients with advanced AMD
![Page 113: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/113.jpg)
Risk Models
• Hageman (2011)– Genetics only model using 13 SNPs– AUC: 0.80– Achieves clinical performance comparable with
models with fewer SNPs that include self-reported and/or non-static risk factors
• Klein (2011)– Joint gene-environment model using two-SNPs– AUC: 0.87
![Page 114: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/114.jpg)
Hageman (2011): Probability of CNV using genetic-only model. Red bars represent controls and blue bars represent patients with CNV.
![Page 115: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/115.jpg)
Are you better off knowing genotype or phenotype?
Klein (2011): Genetic information provides little additional predictive value once the phenotype is known
Demographics & genotype known
Demographics &phenotype known
![Page 116: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/116.jpg)
Risk Models
• Summary– Using genetic information alone it is possible to construct
a model that achieves performance comparable to models that include self-reported and/or non-static risk factors.
– Once phenotype is known, genetic information is of little additional predictive value.
– Risk calculators can identify high-risk individuals for more frequent surveillance and clinical interventions.
![Page 117: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/117.jpg)
Pharmacogenomics
• CFH & AREDS Supplement– Persons homozygous for the CFH high-risk allele (CC) have
a smaller treatment response to the AREDS vitamin/mineral supplement than persons homozygous for the CFH low-risk allele (TT)
– Supplementation was associated with a greater risk reduction of AMD progression (68%) among those with the low-risk TT genotype compared with those with the high-risk CC genotype (11%)
– This is among the first pharmacogenetic studies to suggest interaction between genotype and treatment response
Klein ML, et al. Ophthalmology 2008;115:1019–1025
![Page 118: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/118.jpg)
Response to the AREDS supplement is related to CFH genotype
- Low risk
Persons homozygous for the CFH high-risk allele (CC) have a smaller treatment response than persons
homozygous for the CFH low-risk allele (TT)
Low risk
Low risk4%
23%
![Page 119: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/119.jpg)
Pharmacogenomics
• CFH & Avastin– 86 patients being treated with bevacizumab
(Avastin) were evaluated for associations between treatment response and polymorphisms in the genes CFH and ARMS2.
– Patients homozygous for both CFH risk alleles (CC) had worse visual outcomes than those with the CFH TC and TT genotypes.
Brantley MA, et al. Ophthalmology. 2007;114:2168-73
![Page 120: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/120.jpg)
Pharmacogenomics
• CFH & Lucentis– 156 patients receiving ranibizumab (Lucentis) – Patients homozygous for both CFH risk alleles (CC)
had worse visual outcomes than those with the CFH TC and TT genotypes
– These results suggest that determining patients' CFH genotype may be helpful in the future in tailoring treatment for exudative AMD with intravitreal ranibizumab
Lee AY, et al. Br J Ophthalmol. 2009;93:610-3
![Page 121: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/121.jpg)
Shastry BS. Discovery Medicine. Aug 2011
![Page 122: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/122.jpg)
Pharmacogenomics
• Summary– Genetic information may be used to tailor
strategies for predictive testing, treatment, or prevention.
• Who should be treated and with which drug
– Concerns regarding loss of privacy, impact on employment and insurance discrimination.
• Social, ethical, and economical issues such as genetic discrimination needs to be addressed by regulatory agencies.
Shastry BS. Discovery Medicine. Aug 2011
![Page 123: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/123.jpg)
What’s New in AMD
1. Vitamins2. Genetics3. Anti-VEGF medications4. Fish5. Lutein6. Sunlight and Cataract Surgery7. Lifestyle8. Aspirin9. Implantable Miniature Telescope10. Drug Pipeline
![Page 124: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/124.jpg)
Vitamins
• Vitamin D– Has antiangiogenic, antioxidant and anti-
inflammatory effects– Low vitamin D levels associated with AMD
• B vitamins– Capable of significantly lowering serum levels of
homocysteine– Elevated homocysteine levels are thought to induce
vascular endothelial dysfunction, and has been associated with increased risk of AMD
![Page 125: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/125.jpg)
Vitamin D
• Vitamin D has many diverse metabolic effects– Bone mineralization and the regulation of Ca2+
and phosphorus – Antiangiogenic, antioxidant and anti-inflammatory
effects– Role in cellular proliferation, differentiation and
apoptosis• Biologically plausible that vitamin D may
influence AMD risk
![Page 126: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/126.jpg)
The 3 major sources of vitamin D are:• Sunlight• Milk• Supplements
![Page 127: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/127.jpg)
Vitamin D
• Parekh (2007)– Cross-sectional study of serum vitamin D and early
and advanced AMD from 7752 participants in NHANES– Highest vs lowest quintile of serum vitamin D
• Early AMD: 0.64 (95% CI, 0.5-0.8) odds ratio• Advanced AMD: 1.16 (95% CI, 0.5-3.1) odds ratio
– Milk intake ‘less than weekly’ vs ‘daily or more’ • Early AMD: 0.75 (95% CI, 0.6-0.9) odds ratio
– Vitamin D supplements protective against early AMD only in individuals who did not consume milk daily
Parekh N, et al. Arch Ophthalmol. 2007;125:661-669
![Page 128: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/128.jpg)
Vitamin D
• Millen (2011)– Serum vitamin D levels were assessed 6 years prior to
AMD status in 1313 women aged 50-79 at baseline. – In women <75 yo, having serum
vitamin D concentrations >38 nmol/L was associated with a 48% decreased odds of developing early AMD
– No association found between early AMD and reported time spent outside in direct sunlight
Millen AE, et al. Arch Ophthalmol. 2011; 129: 481–489
![Page 129: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/129.jpg)
Vitamin D
• Morrison (2011)– Cohort of 481 extremely phenotypically discordant siblings
• One sibling has wet AMD and other sibling has no AMD
– UV irradiance was protective of wet AMD• Some UVB exposure, necessary for dermal vitamin D synthesis,
may be protective for AMD when the eyes are protected
– Serum vitamin D levels were higher in unaffected siblings (not statistically significant)
– SNPs in CYP24A1 (enzyme in the vitamin D pathway) increased AMD risk.
• First genetic association between vitamin D and AMD risk.
Morrison MA, et al. Hum Genomics. 2011;5:538-568
![Page 130: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/130.jpg)
Vitamin D
• Summary– Strong evidence that higher serum vitamin D levels
associated with reduced risk of early AMD• Suggestion of protective effect for
neovascular AMD
– Increased consumption of milk and vitamin D supplements may decrease AMD risk
– Sunlight exposure may be protective against AMD if eye protection is worn (UV and blue blocker)
![Page 131: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/131.jpg)
B Vitamins
• Among many other effects, B vitamins have the ability to lower serum homocysteine levels
• Homocysteine is an amino acid that has been found to promote inflammation and oxidative stress in the body
• Elevated homosysteine levels have been associated with higher risk of cardiovascular disease and stroke
![Page 132: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/132.jpg)
Elevated homocysteine levels lead to increased oxidative stress, inflammation, and increased thrombotic tendency. These all increase the risk of endothelial injury and dysfunction.
![Page 133: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/133.jpg)
B Vitamins
• Close relationship between AMD and CVD– Common risk factors
• Smoking, Obesity, HTN, CRP
– Common antecedents: • Inflammation, Oxidative stress, Vascular endothelial dysfunction,
Genetics
– Common interventions• Fish oil, heart-healthy diet, exercise, weight loss
– Speculation: AMD and CVD are two manifestations of a single underlying chronic inflammatory disease of aging
– Hypothesis: If Hcy is assoc with CVD, and if CVD is assoc with AMD, then Hcy may be assoc with AMD
![Page 134: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/134.jpg)
B Vitamins
• Observational evidence – Studies finding AMD associated with elevated Hcy 1. Axer-Siegel (2004) wet AMD only2. Nowak (2005) wet AMD only3. Vine (2005) wet and dry AMD4. Coral (2006) wet AMD only5. Kamburoglu (2006) wet and dry AMD6. Seddon (2006) intermediate or advanced AMD7. Rochtchina (2007) advanced AMD in persons <75yo8. Ates (2009) wet AMD only9. Javadzadeh (2011) wet AMD only
– Studies not finding an association1. Heuberger (2002) NHANES, few late AMD cases, non-fasting2. Wu (2007) BMES, few late AMD cases
![Page 135: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/135.jpg)
B Vitamins
• Christen (2009)– RCT of 5205 women without AMD at baseline
randomized to receive folic acid or placebo for 7.3yr
• 2.5 mg folic acid, 50 mg vitamin B6, 1 mg vitamin B12
– Women assigned to B vitamin supplementation had a statistically significant 35% to 40% decreased risk of developing AMD
Christen WG. Arch Intern Med. 2009;169:335-341
![Page 136: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/136.jpg)
Cumulative incidence rates of confirmed AMD (left) and visually significant (VS) AMD (right). 137 cases of AMD appeared during follow-up, including 70 visually significant (20/30 or worse). After an average 7.3 yrs of follow-up those women on treatment has a 35% lower risk of any AMD and a 40% lower risk of visually significant AMD
![Page 137: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/137.jpg)
B Vitamins
• Folic acid is the first identified means, other than cigarette avoidance, to prevent the onset of AMD
• Should I prescribe this to my patients?– As with any prophylactic therapy, the risk, cost and
convenience of the treatment must be weighed against the risk posed by the disease
– Should be avoided by cancer patients and those on antifolate medications (eg. methotrexate)
Christen WG. Arch Intern Med. 2009;169:335-341
![Page 138: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/138.jpg)
B Vitamins
• What should I prescribe?– WAFACS supplement not commercially available
• 2.5 mg folic acid, 50 mg vitamin B6, 1 mg vitamin B12
– Maximum Hcy-lowering effect: 0.8mg (200% RDA)• RDA: 0.4 mg (400 mcg)
– Tolerable upper intake of folic acid: 1mg • From all sources (food, supplements)• B12 not required if upper limit not exceeded
– Recommendation: ≥200% RDA folic acid plus ≥100% RDA B12 (2.5 mcg)
![Page 139: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/139.jpg)
WAFACS: 2.5 mg folic acid, 50 mg vitamin B6, 1 mg vitamin B12
If you want to prescribe the WAFACS supplement: 5 pills/day
![Page 140: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/140.jpg)
WAFACS: 2.5 mg folic acid, 50 mg vitamin B6, 1 mg vitamin B12
Recommendation ≥200% RDA folic acid
≥100% RDA B12
![Page 141: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/141.jpg)
B Vitamins
• Summary– Elevated serum homocysteine levels associated
with increased risk of neovascular AMD– B vitamin supplements demonstrated to be
protective against developing AMD– B vitamin supplementation
may be recommended for normal patients seeking to reduce their risk of developing AMD
![Page 142: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/142.jpg)
What’s New in AMD
1. Vitamins2. Genetics3. Anti-VEGF medications4. Fish5. Lutein6. Sunlight and Cataract Surgery7. Lifestyle8. Aspirin9. Implantable Miniature Telescope10. Drug Pipeline
![Page 143: Whats New in AMD - 2012](https://reader036.vdocuments.site/reader036/viewer/2022081519/556b0eabd8b42ae47d8b4d91/html5/thumbnails/143.jpg)
Thank You!